Loading stock data…
AZTA
$24.91+0.34 (+1.38%)
Market ClosedLast close May 1
Azenta, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Azenta, Inc. in the Healthcare sector is trading at $24.91. The stock is currently 40% below its 52-week high of $41.73, remaining 17.9% below its 200-day moving average. Technical signals show neutral RSI of 57 and bullish MACD crossover, explaining why AZTA maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.91
Potential Downside
62.1%
Whystock Fair Value$9.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$35.40+42.1%
Range$30.00 – $44.00
Fundamentals
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates thro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.22B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
45.62
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-3.51%
Volume
Today's trading volume
551,385
Recent News
Evercore Cuts Azenta (AZTA) Price Target, Keeps Outperform Rating
Azenta, Inc. (NASDAQ:AZTA) is one of the 10 Best Medical Stocks to Buy Under $30. On April 6, Evercore ISI reduced its price target on Azenta, Inc. (NASDAQ:AZTA) from $45 to $35 while maintaining its Outperform rating on the stock. This update came as part of the firm’s first-quarter preview for the medical technology and […]
Azenta (AZTA) Fell on Operational Challenges and Uneven Execution
Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove […]
2 Cash-Heavy Stocks on Our Buy List and 1 We Turn Down
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
1 Healthcare Stock to Target This Week and 2 We Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 1.9% gain for healthcare stocks has fallen short of the S&P 500’s 6.1% rise.
3 Stocks Under $50 We’re Skeptical Of
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.